Abstract:At present, immunotherapy represented by immune checkpoint inhibitors (ICIs), either by monotherapy or in combination with chemotherapy, has shown benefit in promoting pathological responses and prolonging survival for patients with non‐small cell lung cancer (NSCLC) without oncogenic mutations. Investigation on predictive biomarkers of responses to adjuvant and neoadjuvant therapies is also continuously ongoing. This review focuses on the existing data of current clinical trials of adjuvant and neoadjuvant strategies with ICIs in resectable NSCLC, the exploration of predictive biomarkers, and the perspectives and urgent challenges in the future. Surgery followed by adjuvant chemotherapy is the standard of care for selected patients with early‐stage or locally advanced non‐small cell lung cancer (NSCLC). However, many of these patients still experience postoperative recurrence at 5 years. At present, peri‐operative treatment methods are emerging to prevent early relapse, such as targeted therapy and immunotherapy. Investigation on predictive biomarkers of responses to adjuvant and neoadjuvant therapies is also continuously ongoing. Immunotherapy represented by immune checkpoint inhibitors (ICIs), either by monotherapy or in combination with chemotherapy, has shown benefit in promoting pathological responses and prolonging survival for patients with NSCLC without oncogenic mutations. Exploratory studies have also provided evidence regarding the selection of patients who benefit from ICI‐based perioperative treatment. This review focuses on the existing data of current clinical trials of adjuvant and neoadjuvant strategies with ICIs in resectable NSCLC, the exploration of predictive biomarkers, and the perspectives and urgent challenges in the future.

Adjuvant immunotherapy and targeted therapy in early and locally advanced resectable lung cancer: expanding treatment tentacles?

Adjuvant immunotherapy in early-stage resectable non–small cell lung cancer: A new milestone

Adjuvant treatment of lung cancer: Current status and potential applications of new regimens

Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC

Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives

Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer

Evidence for the evolving role of neoadjuvant and perioperative immunotherapy in resectable non-small cell lung cancer

Adjuvant and neo-adjuvant therapy for non-small cell lung cancer without EGFR mutations or ALK rearrangements

Adjuvant treatment in resected lung cancer

Advancing neoadjuvant therapies in resectable non-small cell lung cancer: implications for novel treatment strategies and biomarker discovery

Perioperative systemic therapies for non-small-cell lung cancer: Recent advances and future perspectives

Expert Consensus on Perioperative Immunotherapy for Local Advanced Non-Small Cell Lung Cancer

The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer

[Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer].

Adjuvant and neo‐adjuvant immunotherapy in resectable non‐small cell lung cancer (NSCLC): Current status and perspectives

Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art

Revamping Non-Small Cell Lung Cancer Treatments in Stages II and III: Preparing Healthcare for Cutting-Edge Immuno-Oncology Regimens

Updated Prognostic Factors in Localized NSCLC

Emerging Evidence from Landmark Clinical Trials on Perioperative Immunotherapy in Resectable Non-Small Cell Lung Cancer

Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients with Early-Stage Non-small Cell Lung Cancer

Several Hotspots of Adjuvant Therapy in Completely Resected Non-Small Cell Lung Cancer